Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
2.08 (1y: -4%)
Market Cap 25.4 M P/E(ttm) 0.30
Enterprise Value 17.67 M P/B 17.30
CRME- NAS (USA)
Cardiome Pharma Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$2.08
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry		 vs
history
Cash to Debt 1.27
CRME's Cash to Debt is ranked lower than
61% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. CRME: 1.27 )
CRME' s 10-Year Cash to Debt Range
Min: 1.27   Max: No Debt
Current: 1.27
Equity to Asset 0.142
CRME's Equity to Asset is ranked lower than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. CRME: 0.142 )
CRME' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.81
Current: 0.14
0.12
0.81
F-Score: 3
Z-Score: 11.6
M-Score: 1.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -3290.20
CRME's Operating margin (%) is ranked lower than
99% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. CRME: -3290.20 )
CRME' s 10-Year Operating margin (%) Range
Min: -11910   Max: 55.5
Current: -3290.2
-11910
55.5
Net-margin (%) -2321.3
CRME's Net-margin (%) is ranked lower than
99% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. CRME: -2321.3 )
CRME' s 10-Year Net-margin (%) Range
Min: -11216.7   Max: 53.7
Current: -2321.3
-11216.7
53.7
ROE (%) -233
CRME's ROE (%) is ranked lower than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. CRME: -233 )
CRME' s 10-Year ROE (%) Range
Min: -233   Max: 69.7
Current: -233
-233
69.7
ROA (%) -40.9
CRME's ROA (%) is ranked lower than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. CRME: -40.9 )
CRME' s 10-Year ROA (%) Range
Min: -114.2   Max: 43.1
Current: -40.9
-114.2
43.1
Revenue Growth (%) -64.1
CRME's Revenue Growth (%) is ranked higher than
65% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. CRME: -64.1 )
CRME' s 10-Year Revenue Growth (%) Range
Min: -64.1   Max: 100
Current: -64.1
-64.1
100
EPS Growth (%) 98.8
CRME's EPS Growth (%) is ranked higher than
64% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. CRME: 98.8 )
CRME' s 10-Year EPS Growth (%) Range
Min: -57.4   Max: 98.8
Current: 98.8
-57.4
98.8
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CRME Guru Trades in Q2 2012

Jim Simons 578,634 sh (+188.55%)
Julian Robertson 1,596,106 sh (unchged)
Pioneer Investments Sold Out
» More
Q3 2012

CRME Guru Trades in Q3 2012

Jim Simons 689,666 sh (+19.19%)
Julian Robertson 1,596,106 sh (unchged)
» More
Q4 2012

CRME Guru Trades in Q4 2012

Jim Simons 884,066 sh (+28.19%)
Julian Robertson Sold Out
» More
Q1 2013

CRME Guru Trades in Q1 2013

Jim Simons 987,166 sh (+11.66%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2012-12-31 Sold Out 0.11%$0.25 - $0.5 $ 2.08571%0
George Soros 2011-12-31 Sold Out 0.0008%$1.87 - $3.57 $ 2.08-22%0
Julian Robertson 2011-09-30 Reduce -22.89%0.69%$3.32 - $5.59 $ 2.08-48%1952588
George Soros 2011-06-30 New Buy$3.85 - $5.77 $ 2.08-56%13200
Julian Robertson 2011-03-31 Add 6.15%0.16%$4.26 - $6.99 $ 2.08-65%2532340
Julian Robertson 2010-12-31 Add 9.55%0.34%$4.6 - $6.55 $ 2.08-63%2385615
George Soros 2010-12-31 Sold Out $4.6 - $6.55 $ 2.08-63%0
Julian Robertson 2010-09-30 Add 10.01%0.4%$5.97 - $9.31 $ 2.08-71%2177615
Julian Robertson 2010-06-30 New Buy3.53%$6.92 - $8.68 $ 2.08-74%1979405
George Soros 2010-06-30 New Buy$6.92 - $8.68 $ 2.08-74%10900
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 0.30
CRME's P/E(ttm) is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. CRME: 0.30 )
CRME' s 10-Year P/E(ttm) Range
Min: 0.25   Max: 11642.2
Current: 0.3
0.25
11642.2
P/B 17.30
CRME's P/B is ranked lower than
98% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. CRME: 17.30 )
CRME' s 10-Year P/B Range
Min: 0.76   Max: 30.31
Current: 17.3
0.76
30.31
P/S 61.35
CRME's P/S is ranked lower than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. CRME: 61.35 )
CRME' s 10-Year P/S Range
Min: 3.19   Max: 553.33
Current: 61.35
3.19
553.33
PFCF 208.00
CRME's PFCF is ranked lower than
57% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. CRME: 208.00 )
CRME' s 10-Year PFCF Range
Min: 5.82   Max: 381
Current: 208
5.82
381
EV-to-EBIT 500
CRME's EV-to-EBIT is ranked lower than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. CRME: 500 )
CRME' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 158.2
Current: 500
4.5
158.2

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 29.7
CRME's Price/Net Cash is ranked lower than
71% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.70 vs. CRME: 29.7 )
CRME' s 10-Year Price/Net Cash Range
Min: 5.5   Max: 378.8
Current: 29.7
5.5
378.8
Price/Net Current Asset Value 104
CRME's Price/Net Current Asset Value is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. CRME: 104 )
CRME' s 10-Year Price/Net Current Asset Value Range
Min: 10.8   Max: 233
Current: 104
10.8
233
Price/Tangible Book 20.8
CRME's Price/Tangible Book is ranked lower than
67% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. CRME: 20.8 )
CRME' s 10-Year Price/Tangible Book Range
Min: 3.6   Max: 35.3
Current: 20.8
3.6
35.3
Price/Median PS Value 1.3
CRME's Price/Median PS Value is ranked higher than
57% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. CRME: 1.3 )
CRME' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 5.8
Current: 1.3
0.1
5.8
Earnings Yield (Greenblatt) 0.20
CRME's Earnings Yield (Greenblatt) is ranked higher than
62% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. CRME: 0.20 )
CRME' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 22
Current: 0.2
0.2
22
Forward Rate of Return (Yacktman) -54.7
CRME's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. CRME: -54.7 )
CRME' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.3   Max: -5.7
Current: -54.7
-18.3
-5.7

Business Description

Cardiome Pharma Corporation was incorporated in December 12, 1986 under the name Nortran Resources Ltd. In June 2001, it changed its name to Cardiome Pharma Corp. It is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases. Its current drug development efforts are focused on the treatment of atrial arrhythmias; a Phase 1 program for GED-aPC, an engineered analog of human activated protein C; and a pre-clinical program directed at improving cardiovascular function. Vernakalant is a new chemical entity designed to treat atrial fibrillation, with the potential to overcome the limitations of current drugs used to treat the disease. Its mechanism of action involves the selective blockade of multiple ion channels in the heart that are known to be active during episodes of atrial fibrillation. The drug is currently being developed for two potential applications: vernakalant (IV) is being evaluated as an intravenous pharmacological converting agent designed to terminate an atrial fibrillation episode and return the heart to normal rhythm; and vernakalant (oral) is being evaluated as an oral maintenance therapy for the long-term prevention of atrial fibrillation recurrence. The Company continues to conduct early stage research on internal assets focusing on improvement of cardiovascular function. The life sciences industry is characterized by extensive research efforts, rapid technology change and intense competition. It is subject to federal, provincial, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products.
Company Website
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:COM.Canada, CKO.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial